/EIN News/ -- Dublin, July 03, 2018 (GLOBE NEWSWIRE) -- The "New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030" report has been added to ResearchAndMarkets.com's offering. Cancer therapeutics continues to be one of the most active segments, in terms of drug development efforts, within the pharmaceutical industry. In fact, in the past five years, USFDA has approved more than 70 drugs for the treatment of different types of cancer. However, there is still a pressing need to develop more specific and potent therapeutics to combat this complex, life threatening clinical condition. According to the National Institutes of Health, the economic burden of cancer care in the US was estimated to be over USD 147 billion in 2017. As the global population continues to increase, the number of cancer patients is likely to rise as well; by 2030, it is estimated that about 21.6 million people are likely to be newly diagnosed with … [Read more...] about Cancer Therapies: World Industry Analysis & Forecasts to 2030
Adoptive t cell therapy clinical trials
THE MAGIC MICROSCOPIC particles that might change the world — and in the process, permanently burnish Seattle’s spot on the big, ascent-of-man scientific map — are, at this very moment, being carted about on a medical campus one short traffic jam away from the shores of Lake Union. Their mode of transport: a thermo-molded plastic lunch cooler, of the sort one might nab at Walmart to carry a baloney sandwich and some freshly cured herring out for a day of salmon fishing on Puget Sound. The little coolers are ubiquitous at the Fred Hutchinson Cancer Research Center, which four decades ago pioneered a groundbreaking treatment for blood cancers — the bone-marrow transplant, now an older science that still saves lives, but not without harrowing side effects. What has changed in cancer research since then? Almost everything. But the research growing from those transplants is blossoming today into what could be, at last, actual cures for common cancers that have long … [Read more...] about The Hutch closes in on a cancer cure
Story highlights Stem cell therapies could treat various diseases, if shown to be safe and effective FDA officials reveal new efforts to regulate, but not hold back, these therapies (CNN)Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the development of stem cell therapies proved to be safe and effective. Dr. Scott Gottlieb, the FDA commissioner, and Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, co-authored a new paper detailing the delicate balance between safety and innovation when it comes to the possibilities of using stem cells in medicine. "Our aim is to refashion our traditional tools for regulation to meet the challenges and opportunities presented by such highly innovative products as cell-based regenerative medicine," they wrote in the paper, published Thursday in the New England Journal of Medicine. … [Read more...] about FDA sets path for stem cell therapies
By the time Peter Travers’ wife took her last breath in May 2016, she had fought cancer 12 times over the span of 18 years.She had fought a good fight, and during the last three years of her life, she even used the experimental cancer therapy device that her husband had built for her.“She became a very intelligent guinea pig and helped us improve the device,” said Travers, 65, of Longwood.It all started in 2012, when Laurie Travers’ cancer came back, this time around her lungs.“It was the beginning of the end,” said Travers. “I found her in the garage one day getting ready for a garage sale, and I said, ‘Why are you doing this now?’ And she said, ‘You don't know what to do with all this stuff after I'm gone.”Desperate to save his wife, Travers began sifting through new studies and clinical trials until he stumbled upon a device that used electrical fields to kill cancer cells.Called Tumor Treating Fields, the therapy was … [Read more...] about LifeBridge 10000 developing cancer therapy with electric fields
Apple (NASDAQ: AAPL) plans to open healthcare clinics for its Cupertino employees and their families that will rely heavily on its technology. The decision reflects Apple's commitment to leveraging its ecosystem to revolutionize this $3.3 trillion dollar market. Could Apple become your primary care provider?In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss Apple's plan and what it may mean for shareholders. Also, the two explain how Gilead Sciences' (NASDAQ: GILD) new gene-editing partnership with Sangamo Therapeutics (NASDAQ: SGMO) could turn it into an oncology powerhouse.A full transcript follows the video.10 stocks we like better than WalmartWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*David and Tom just revealed what they believe are the ten … [Read more...] about Apple’s Cure for Soaring Costs? Tech-Savvy Healthcare Clinics
Image source: The Motley Fool. Gilead Sciences, Inc. (NASDAQ: GILD) Q4 2017 Earnings Conference Call Feb. 6, 2018, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, thank you for standing by, and welcome to the Gilead Sciences Fourth Quarter 2017 Earnings Conference Call. My name is Candace and I will be your conference operator today. At this time, all participants are on a listen-only mode, and as a reminder, this conference call is being recorded. I would now like to turn the call over to Sung Lee, Vice President of Investor Relations. Please go ahead. Sung Lee -- Vice President of Investor Relations Thank you, Candace, and good afternoon everyone. Just after market close today, we issued a press release with earnings results for the fourth quarter and full year 2017. The press release and detailed slides are available on the Investor Relations section of Gilead website. The … [Read more...] about Gilead Sciences Inc. (GILD) Q4 2017 Earnings Conference Call Transcript
What happened Shares of the clinical-stage cell therapy company Bellicum Pharmaceuticals (NASDAQ: BLCM) are in free fall on Wednesday. The biotech announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. Bellicum's shares are down by 33.5% at 10:11 a.m EST on heavy volume in response to this news. Image source: Getty Images. So what This clinical setback may be the beginning of the end for Bellicum. The company has staked the bulk of its value proposition on producing a safer adoptive cell therapy than the current industry leaders. So, a serious safety issue like encephalopathy -- if shown to be treatment-related -- would be a big blow to … [Read more...] about Why Bellicum Pharmaceuticals Stock Is Crashing Today
Since its IPO in late 2014, the Houston-based adoptive cell therapy company Bellicum Pharmaceuticals (NASDAQ: BLCM) has lost an incredible 65% of its value. This enormous drop is particularly noteworthy because it's occurred against the backdrop of an ever-rising chimeric antigen receptor T-cell (CAR-T) therapy space. In the past four months alone, for instance, Gilead Sciences (NASDAQ: GILD) gobbled up Kite Pharma for nearly $12 billion, and Celgene Corp. announced it was acquiring the remaining shares of Juno Therapeutics for a whopping $9 billion earlier this week. Image source: Getty Images. Meanwhile, bluebird bio (NASDAQ: BLUE) stock has also taken flight, thanks in large part to the stellar success of its experimental CAR-T therapy, bb2121. Its treatment for multiple myeloma is being developed with Celgene. And even smaller players like Atara Biotherapeutics, which is developing an off-the-shelf CAR-T product candidate, have benefited immensely from Wall Street's … [Read more...] about Will 2018 Be Bellicum Pharmaceuticals, Inc.’s Best Year Yet?
Rumors are swirling that Celgene Corp. (NASDAQ: CELG) may pay billions of dollars to buy Juno Therapeutics (NASDAQ: JUNO) lock, stock, and barrel. Do these rumors make sense? In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes is joined by Todd Campbell to discuss this potential acquisition and Celgene's future. Also, they explain how Teladoc (NYSE: TDOC) is disrupting the $57 billion market for primary and speciality doctor visits. Is this the future of healthcare? A full transcript follows the video. 10 stocks we like better than Wal-Mart When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Wal-Mart wasn't one of them! That's right -- they think these 10 stocks are even better buys. … [Read more...] about Healthcare: Is Celgene Going to Buy Juno Therapeutics?
What happened Shares of the clinical-stage adoptive cell therapy company Bellicum Pharmaceuticals (NASDAQ: BLCM) fell by 16.9% in December, according to data from S&P Global Market Intelligence. Even more concerning, the Houston-based biotech lost over 38% of its value in 2017. The catalyst? Bellicum's shares have been declining simply because the company continues to fall further and further behind the industry leaders in adoptive cell therapy. Image source: Getty Images. So what Gilead Sciences and Novartis both gained regulatory approvals for their genetically modified cell therapies last year, and Juno Therapeutics is close to bringing a third product to market perhaps as early as late 2018. Unfortunately, Bellicum is also contending with several other would-be competitors as well, implying that the company may not be able to carve out a profitable niche in this increasingly crowded field. Now what Bellicum's saving grace, though, may be its controllable switch … [Read more...] about Bellicum Pharmaceuticals Is Failing to Capture Investors’ Imagination